Elimination of hepatitis C program

2015

"The following groups of patients are considered as priority:
- patients with compensated cirrhosis of liver (F4);
- patients with severe hepatic fibrosis (F3);
- patients with decompensated cirrhosis (candidates to make the liver transplantation);
- patients with liver transplantation and HCV reinfection;
- patients with clinically important extrahepatic evidence of HCV infection, e.g. mixed cryoglobulinemia of type 2 and type 3 (e.g. vasculitis), proteinuria, nephrosis syndrome or membranoproliferative glomerulonephritis, insular diabetes type 2, porphyria cutanea tarda hereditaria, etc;
- patients with AIDS and/or HBV co-infection.
Before the patients (included in this program) with positive results on anti-C hepatitis virus antibodies begin to treat they have to make other necessary examinations:
a) visit to doctor;
b) quantitative determination of HCV RNA in blood by PCR method; the patients with (-) negative HCV RNA aren't discussed as beneficiaries any more and the examinations to evaluate the hepatic fibrosis won't be done for them;
c) total hematology analysis, functional tests of liver (ALT, AST examinations) and determination of level of fibrosis by FIB-4 test counting are done for the patients with positive HCV RNA results;
d) in case if FIB-4 indicator is between 1.45 - 3.25 liver elastography is done additionally;
e) the following examinations are done for the patients with hepatic fibrosis of F3, F3-F4 and F4 levels determined by FB-4 test and liver elastography
f) determination of HCV genetic type by PCR method; g) HBsAg, Anti-HBs, G-GT, alkaline phosphatase, bilirubin (direct and total), creatinin, glucose, albumin, INR, ANA, TSH, ultrasound examination of abdomen; h) all examinations considered by the sub-component are done for the patients with clinically important extrahepatic evidence of HCV infection (mixed cryoglobulinemia of type 2 and type 3 (e.g. vasculitis), proteinuria, nephrosis syndrome or membranoproliferative glomerulonephritis, insular diabetes type 2, porphyria cutanea tarda hereditaria, etc.), also the patients with AIDS and/or HBV co-infection."